Urinary β2-microglobulin as a prognostic and treatment-associated biomarker in anti-MDA5 antibody-positive DM with interstitial lung disease.

OBJECTIVES: We evaluated urinary β2-microglobulin (U-β2M) as a prognostic and treatment-associated marker in anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (MDA5-DM) with interstitial lung disease (ILD). METHODS: We retrospectively identified 68 patients with MDA5-DM admitted between January 2004 and March 2023. After excluding five patients with confirmed or indeterminate outcomes unrelated to MDA5-DM, 63 patients were included (20 deaths, 43 survivors); baseline U-β2M was available in 52 patients (16 deaths, 36 survivors). Pre-treatment levels, longitudinal changes, and correlations with serum ferritin and anti-MDA5 antibody titres were evaluated. RESULTS: At admission, U-β2M levels were significantly higher in the deceased group (p = 0.011). U-β2M predicted mortality (area under the curve 0.72), comparable to serum ferritin and anti-MDA5 antibody titres (0.68 and 0.69), and significantly higher than serum Krebs von den Lungen-6 (KL-6) (0.50; p = 0.0394). U-β2M correlated with anti-MDA5 antibody titres (p < 0.0001) and serum ferritin (p < 0.0001). Post-treatment U-β2M decreased in survivors (p = 0.009) but increased in deceased patients (p = 0.009). Serum ferritin did not change significantly (p = 0.086 and p = 0.782, respectively); KL-6 did not change significantly in survivors (p = 0.059) but increased in the deceased group (p < 0.0001). CONCLUSION: U-β2M is a promising, non-invasive prognostic and treatment-associated marker for MDA5-DM with ILD, showing more pronounced longitudinal change than serum ferritin and KL-6. However, given the retrospective, single-center design of this study, prospective validation in larger cohorts is warranted.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-11-13
DOI
https://doi.org/10.1093/rheumatology/keag632
Primary Topic
Inflammatory Myopathies and Dermatomyositis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Urinary β2-microglobulin as a prognostic and treatment-associated biomarker in anti-MDA5 antibody-positive DM with interstitial lung disease.

Takao Nagashima, Kojiro Sato, Jun Nakamura
1 links
PubMed
Inflammatory Myopathies and Dermatomyositis
article

Urinary β2-microglobulin as a prognostic and treatment-associated biomarker in anti-MDA5 antibody-positive DM with interstitial lung disease.

Takao Nagashima, Kojiro Sato, Jun Nakamura
article en

Abstract

OBJECTIVES: We evaluated urinary β2-microglobulin (U-β2M) as a prognostic and treatment-associated marker in anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (MDA5-DM) with interstitial lung disease (ILD). METHODS: We retrospectively identified 68 patients with MDA5-DM admitted between January 2004 and March 2023. After excluding five patients with confirmed or indeterminate outcomes unrelated to MDA5-DM, 63 patients were included (20 deaths, 43 survivors); baseline U-β2M was available in 52 patients (16 deaths, 36 survivors). Pre-treatment levels, longitudinal changes, and correlations with serum ferritin and anti-MDA5 antibody titres were evaluated. RESULTS: At admission, U-β2M levels were significantly higher in the deceased group (p = 0.011). U-β2M predicted mortality (area under the curve 0.72), comparable to serum ferritin and anti-MDA5 antibody titres (0.68 and 0.69), and significantly higher than serum Krebs von den Lungen-6 (KL-6) (0.50; p = 0.0394). U-β2M correlated with anti-MDA5 antibody titres (p < 0.0001) and serum ferritin (p < 0.0001). Post-treatment U-β2M decreased in survivors (p = 0.009) but increased in deceased patients (p = 0.009). Serum ferritin did not change significantly (p = 0.086 and p = 0.782, respectively); KL-6 did not change significantly in survivors (p = 0.059) but increased in the deceased group (p < 0.0001). CONCLUSION: U-β2M is a promising, non-invasive prognostic and treatment-associated marker for MDA5-DM with ILD, showing more pronounced longitudinal change than serum ferritin and KL-6. However, given the retrospective, single-center design of this study, prospective validation in larger cohorts is warranted.

PubMed
Jichi Medical University (JP), Jichi Medical University Saitama Medical Center (JP), Saitama Medical Center, Saitama Medical University (JP), Saitama Medical University (JP)
Good health and well-being
Inflammatory Myopathies and Dermatomyositis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon